Product Description
a signal transducer and activator of transcription 3 phosphorylation inhibitor for patients with relapsed or refractory hematological malignancies (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25912076/)
Mechanisms of Action: STAT3 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin|Multiple Myeloma|Chronic Lymphoid Leukemia|Mouth Cancer|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Leukemia, Plasma Cell|Acute Myeloid Leukemia|Melanoma|Nasopharyngeal Cancer|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Gastrointestinal Cancer|Acute Respiratory Distress Syndrome|Gastrointestinal Stromal Tumors
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NP01/27/13 | P1 |
Terminated |
Nasopharyngeal Cancer |
2015-05-01 |
|
| JapicCTI-111478 | P1 |
Completed |
Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Lymphoma, Non-Hodgkin|Acute Myeloid Leukemia|Leukemia, Plasma Cell|Multiple Myeloma|Chronic Lymphoid Leukemia |
2014-04-01 |
|
| JapicCTI-111478 | P1 |
Completed |
Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Chronic Myeloid Leukemia|Lymphoma, Non-Hodgkin|Multiple Myeloma|Chronic Lymphoid Leukemia |
2013-12-31 |
|
| NCT01184807 | P1 |
Completed |
Non-Small-Cell Lung Cancer|Gastrointestinal Cancer|Acute Respiratory Distress Syndrome|Small Cell Lung Cancer|Gastrointestinal Stromal Tumors|Melanoma |
2013-06-01 |